Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Free Report) – HC Wainwright raised their FY2026 earnings estimates for shares of Syndax Pharmaceuticals in a research report issued to clients and investors on Tuesday, November 3rd. HC Wainwright analyst A. Maldonado now forecasts that the company will earn ($2.06) per share for the year, up from their prior estimate of ($2.07). HC Wainwright has a “Buy” rating and a $36.00 price objective on the stock. The consensus estimate for Syndax Pharmaceuticals’ current full-year earnings is ($2.03) per share. HC Wainwright also issued estimates for Syndax Pharmaceuticals’ Q4 2026 earnings at ($0.47) EPS, Q1 2027 earnings at ($0.42) EPS, Q2 2027 earnings at ($0.37) EPS, Q3 2027 earnings at ($0.30) EPS, Q4 2027 earnings at ($0.27) EPS, FY2027 earnings at ($1.36) EPS, FY2028 earnings at ($0.08) EPS, FY2029 earnings at $1.54 EPS and FY2030 earnings at $2.42 EPS.
SNDX has been the subject of a number of other research reports. UBS Group reissued a “buy” rating on shares of Syndax Pharmaceuticals in a research note on Thursday, October 1st. JPMorgan Chase & Co. cut their price target on shares of Syndax Pharmaceuticals from $44.00 to $40.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 11th. Weiss Ratings raised shares of Syndax Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday. Bank of America reiterated a “buy” rating on shares of Syndax Pharmaceuticals in a report on Wednesday, August 5th. Finally, Mizuho set a $43.00 price objective on Syndax Pharmaceuticals in a research report on Tuesday. Ten equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $41.60.
Get Our Latest Stock Report on SNDX
Syndax Pharmaceuticals Trading Down 26.9%
NASDAQ:SNDX opened at $10.45 on Thursday. The firm’s fifty day moving average is $16.76 and its 200-day moving average is $20.12. The company has a debt-to-equity ratio of 38.95, a quick ratio of 6.44 and a current ratio of 4.69. Syndax Pharmaceuticals has a 52 week low of $9.99 and a 52 week high of $25.59. The firm has a market cap of $925.97 million, a P/E ratio of -4.43 and a beta of 0.48.
Syndax Pharmaceuticals (NASDAQ:SNDX – Get Free Report) last released its quarterly earnings results on Monday, November 2nd. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by ($0.05). The firm had revenue of $83.30 million for the quarter, compared to the consensus estimate of $81.38 million. Syndax Pharmaceuticals had a negative return on equity of 804.38% and a negative net margin of 72.32%. The firm’s revenue for the quarter was up 81.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.70) EPS.
Insider Buying and Selling
In other Syndax Pharmaceuticals news, Director Dennis Podlesak sold 8,000 shares of the firm’s stock in a transaction on Thursday, October 29th. The shares were sold at an average price of $14.21, for a total value of $113,680.00. Following the completion of the sale, the director directly owned 239,763 shares in the company, valued at approximately $3,407,032.23. This trade represents a 3.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 4.80% of the company’s stock.
Hedge Funds Weigh In On Syndax Pharmaceuticals
Institutional investors have recently made changes to their positions in the stock. CenterBook Partners LP bought a new position in Syndax Pharmaceuticals in the third quarter worth approximately $5,137,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Syndax Pharmaceuticals in the third quarter valued at approximately $86,000. China Universal Asset Management Co. Ltd. grew its stake in Syndax Pharmaceuticals by 15.5% in the third quarter. China Universal Asset Management Co. Ltd. now owns 16,293 shares of the company’s stock valued at $297,000 after acquiring an additional 2,191 shares during the period. Sterling Capital Management LLC increased its holdings in shares of Syndax Pharmaceuticals by 846.6% during the third quarter. Sterling Capital Management LLC now owns 2,963 shares of the company’s stock valued at $56,000 after acquiring an additional 2,650 shares in the last quarter. Finally, Inspire Investing LLC increased its holdings in shares of Syndax Pharmaceuticals by 10.2% during the third quarter. Inspire Investing LLC now owns 34,122 shares of the company’s stock valued at $641,000 after acquiring an additional 3,157 shares in the last quarter.
Syndax Pharmaceuticals News Roundup
Here are the key news stories impacting Syndax Pharmaceuticals this week:
- Positive Sentiment: Third-quarter revenue of $83.3 million topped analyst expectations and rose 81.9% year over year. Coverage also pointed to a Revuforj rebound and a higher Niktimvo margin outlook, supporting the commercial outlook. Article: Syndax misses on EPS but Revuforj rebound and higher Niktimvo margin guide sharpen the commercial story
- Positive Sentiment: Syndax said 19 Revuforj and Niktimvo abstracts were accepted for the ASH 2026 meeting, including seven oral presentations. The data cover revumenib across several acute leukemia settings and longer-term axatilimab results in chronic graft-versus-host disease, offering potential catalysts for investor interest. Article: Syndax highlights acceptance of 19 abstracts at ASH 2026
- Neutral Sentiment: The company appointed Aaron A. Ondrey as chief financial officer as part of a CFO transition. The announcement provides a leadership change but no clear immediate financial or operating impact. Article: Syndax announces CFO transition
- Neutral Sentiment: Syndax plans an investor event during the ASH meeting on December 14, which may give management a platform to discuss its products and pipeline; the event itself does not change near-term results. Article: Syndax to host ASH investor event
- Negative Sentiment: The company’s third-quarter loss per share was $0.55, missing the $0.50 loss analysts expected. Reports also cited pipeline setbacks, weighing against the revenue growth and sharpening concerns about execution. Article: Syndax reports third-quarter earnings results
- Negative Sentiment: Pomerantz LLP announced an investigation into claims on behalf of Syndax investors. The notice may add a legal overhang, though it does not establish wrongdoing. Article: Pomerantz investigates claims on behalf of Syndax investors
Syndax Pharmaceuticals Company Profile
Syndax Pharmaceuticals, Inc (NASDAQ:SNDX) is a biopharmaceutical company focused on developing and commercializing therapies for cancer and immune-related diseases. Founded in 2005 and headquartered in Waltham, Massachusetts, the company develops medicines designed to address genetically defined cancers and serious complications associated with cancer treatment.
Syndax’s lead product is Revuforj (revumenib), an oral menin inhibitor approved in the United States for the treatment of relapsed or refractory acute leukemia with a KMT2A translocation in eligible adults and children.
See Also
- Five stocks we like better than Syndax Pharmaceuticals
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
